Alps Advisors Inc Autolus Therapeutics PLC Transaction History

Alps Advisors Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.32 - $3.36 $2,150 - $3,114	927 Added 0.73%	128,147 $298,000
Q2 2023 Aug 14, 2023	BUY	$1.64 - $3.21 $208,640 - $408,376	127,220 New	127,220 $302,000
Q3 2022 Nov 14, 2022	SELL	$2.04 - $3.76 $8,718 - $16,070	-4,274 Reduced 7.92%	49,657 $106,000
Q2 2022 Aug 11, 2022	SELL	$2.04 - $4.68 $80,584 - $184,869	-39,502 Reduced 42.28%	53,931 $153,000
Q1 2022 May 16, 2022	BUY	$3.52 - $5.46 $31,859 - $49,418	9,051 Added 10.73%	93,433 $390,000
Q4 2021 Feb 09, 2022	BUY	$5.1 - $7.0 $430,348 - $590,674	84,382 New	84,382 $438,000

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $208M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.